Sign inJoin waitlistJoin the waitlist

Manali Bhave

Medical Director, Phase I Clinical Trials Unit · Winship Cancer Institute at Emory Midtown

Credentials: · · · ·

History

Phase I Clinical Trials Unit · Winship Cancer Institute at Emory Midtown
Present
Emory University School of Medicine
Present
Winship Cancer Institute at Emory Midtown
Present

Northwestern University
2017–2018
Hematology and Medical Oncology
University of Michigan
2014–2017
Internal Medicine
Northwestern University
2011–2014
Feinberg School of Medicine
2007–2011

Research

Patients transplanted for nonalcoholic steatohepatitis are at increased risk for postoperative cardiovascular events
Hepatology · 2012 · 178 citations
Acquired hemophilia a: diagnosis, aetiology, clinical spectrum and treatment options
Review · Autoimmunity Reviews · 2011 · 94 citations
Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial
Annals of Oncology · 2023 · 58 citations

Kevin Kalinsky
10 papers
Mylin Torres
5 papers
CM
Cynthia Ma
4 papers
KJ
Komal Jhaveri
4 papers
Peter Kaufman
4 papers
Cathy Graham
3 papers
David Schuster
3 papers
GU
Gary Ulaner
3 papers
IL
Ismaheel Lawal
3 papers · 3 as a resident
Jane Meisel
3 papers
Jeffrey Aldrich
3 papers
RI
Roohi Ismail-Khan
3 papers

Clinical trials

High Dose Radiation Therapy With Pembrolizumab and Chemotherapy for the Treatment of Patients With PD-L1 Positive Metastatic Triple Negative Breast Cancer
Principal investigator · Recruiting · Phase 2
Emory University
2025–2028
Transcutaneous Electrical Nerve Stimulation in Chemotherapy Induced Peripheral Neuropathy in Patients With Stage I-III Early Stage Breast Cancer
Principal investigator · Terminated
Emory University
2022–2025
A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
Site PI · Recruiting · Phase 2
Eli Lilly and Company
2026–2029
A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer
Site PI · Recruiting · Phase 1
Stemline Therapeutics, Inc.
2024–2029